China Radiotherapy Market Report 2022 to 2030

China Radiotherapy Market Analysis

$ 3999

By 2030, it is anticipated that the China Radiotherapy Market will reach a value of $991 Mn from $555 Mn in 2022, growing at a CAGR of 7.5% during 2022-30. The Radiotherapy Therapeutics Market in China is dominated by a few domestic players such as Sinopharm, Accuray China Medical Equipment, and Shanghai Elekta Medical Equipment. The radiotherapy market in China is segmented into different types, technologies, procedures, applications, and end-users. The major risk factors associated with awareness of radiotherapy shortage of skilled staff, government initiatives, and reimbursement policy. The demand for China Radiotherapy is increasing on account of the rise in cancer cases in the country.

ID: IN10CNPH043 CATEGORY: Pharmaceuticals GEOGRAPHY: China AUTHOR: Dr. Vishwa Modhia

Buy Now

China Radiotherapy Market Analysis Summary

By 2030, it is anticipated that the China Radiotherapy Market will reach a value of $991 Mn from $555 Mn in 2022, growing at a CAGR of 7.5% during 2022-30.

China is an upper middle-income developing country in East Asia bordering the East China Sea, Korea Bay, and the South China Sea. According to the Chinese government's Healthy China Action Plan, cancer is one of China's five high-priority sickness categories, with patients suffering from severe health burdens and unmet demands (2019-2030). China accounts for more than half of the global burden of gastric, hepatocellular, and oesophageal cancer.

60% of the 393 assets in development by China's biopharmaceutical industry are aimed at cancer types that have the highest incidence rates: lung, colon, stomach, liver, and breast cancer. Through a combination of in-house assets and partnerships, local biotech firms are diversifying their immuno-oncology portfolios. China's government spent 5.6 % of its GDP on healthcare in 2020.

China Radiotherapy Market Analysis

Market Dynamics

Market Growth Drivers Analysis

In the previous 30 years, China has had a great economic expansion, and radiation oncology has obviously improved in terms of equipment and use, despite a shortage of facilities and manpower. Accelerating oncology innovation in China is critical to making progress in managing China's oncology burden and ensuring that patients receive better, more accessible, and equitable treatment options, all within the context of transformational ecosystem-shaping initiatives grounded in the local environment. Manufacturing is highly valued in China, whereas the services industry is growing as a result of e-commerce trends. These aspects could boost China's, Radiotherapy Market.

Market restraints

The number of oncologists per million people in China increased from 14 in 2005 to 26 in 2018, but the country is still a long way from meeting the US benchmark of 60 oncologists per million people. Only half of the patients who needed radiation received it in Mainland China. The local Chinese Society of Clinical Oncology Guidelines, which take drug accessibility and regional development disparities into account, are strongly recommended for clinical practice. China lags behind the United States in terms of innovation, as measured by the number of targets in clinical trials. Clinical investigations in the United States now cover 550 targets, compared to 160 in China. These factors may deter new entrants into the China Radiotherapy Market.

Competitive Landscape

Key Players

Shanghai Elekta Medical Equipment: Shanghai Elekta Medical Equipment is a joint venture between Elekta AB and China National Nuclear Corporation (CNNC) that produces radiation therapy and radiosurgery equipment and software for the Chinese market
Accuray China Medical Equipment: Accuray China is a subsidiary of Accuray Inc., an American company that produces radiation therapy and radiosurgery equipment and software. Accurate China provides sales, service, and support for their products in China
Varian Medical Systems China: Varian Medical Systems China is the Chinese subsidiary of Varian Medical Systems, an American company that produces medical devices and software for the treatment of cancer and other medical conditions
China National Pharmaceutical Group Corporation (Sinopharm): Sinopharm is a state-owned company in China that provides pharmaceutical and healthcare products and services
Jiangsu Hengrui Medicine: Jiangsu Hengrui Medicine is a Chinese company that produces pharmaceutical products and medical devices

Recent Notable Updates

March 2023: Elekta launched a cooperative venture with China National Pharmaceutical Group Co., Ltd. (Sinopharm) to expand the use of radiation therapy in so-called lower-tier cities, where around 70% of the population lives. Sinopharm is involved in many sectors of healthcare, not just medicines, such as research and development, production, transportation and distribution, and healthcare delivery. Elekta will improve access to over 1,000 medical institutions in minor cities within Sinopharm Group's service network as part of the joint venture arrangement.

Healthcare Policies and Reimbursement Scenarios

In China, radiotherapy is regulated and reimbursed by the National Healthcare Security Administration (NHSA). The regulation of radiotherapy in China is overseen by the National Health Commission, which establishes guidelines and protocols for the use of radiotherapy in the treatment of cancer and other medical conditions. The NHSA provides reimbursement for a range of radiotherapy technologies, including intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT), among others.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Radiotherapy Segmentation

By Type (Revenue, USD Billion):

External Beam Radiation Therapy
Linear Accelerators
Compact Advanced Radiotherapy Systems
Cyberknife
Gamma Knife
?Tomotherapy
Proton Therapy
Cyclotron
?Synchrotron
Internal Beam Radiation Therapy
Brachytherapy
Seeds
Applicators and Afterloaders
Electronic Brachytherapy
Systemic Radiation Therapy
?Others

?By Technology (Revenue, USD Billion):

External Beam Radiotherapy
Intensity-Modulated Radiation Therapy (IMRT)
Image-Guided Radiation Therapy (IGRT)
Stereotactic Radiation Therapy (SRT)
3D Conformal Radiation Therapy (3D-CRT)
Particle Therapy
Internal Beam Radiotherapy
Brachytherapy
High-Dose Rate Brachytherapy
Low-Dose Rate Brachytherapy
Image-Guided Brachytherapy
Pulse-Dose Rate Brachytherapy
Systemic Radiation Therapy
Intravenous Radiotherapy
Oral Radiotherapy?

By Application (Revenue, USD Billion):

Breast Cancer
Cervical Cancer
Colon and rectum Cancers
Stomach Cancer
Lung Cancer
Prostate Cancer
Skin Cancer
Liver Cancer
Other types of cancer

By End User (Revenue, USD Billion):

Hospitals
Radiotherapy Centers & Ambulatory Surgery Centers
?Cancer Research Institutes

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.

We value your inquiry and offer free customization with every report to fulfil your exact research needs.

Yes, I have read the privacy policy

By 2030, it is anticipated that the China Radiotherapy market will reach a value of $991 Mn from $555 Mn in 2022, growing at a CAGR of 7.5% during 2022-2030.

In China, radiotherapy is regulated and reimbursed by the National Healthcare Security Administration (NHSA).

The Radiotherapy Therapeutics Market in China is dominated by a few domestic players such as Sinopharm, Accuray China Medical Equipment, and Shanghai Elekta Medical Equipment.